Advertisement


Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

2023 ASCO Annual Meeting

Advertisement

Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The pelvic recurrence rate at 3 years in the women who underwent simple hysterectomy is not inferior to those who had radical hysterectomy. In addition, fewer surgical complications and better quality of life were observed with simple hysterectomy (LBA5511).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the standard treatment for the management of women with early stage cervical cancer is a radical hysterectomy, which involves the removal of the uterus and cervix, of course, but also the removal of parametrial tissue in upper vagina, which is what is associated with the greater morbidity of the procedure, as well as the potential complications and quality of life impacts issues on the bowel and bladder and sexual function. What we've noticed in retrospective studies is that the rate of parametrial infiltration in women meeting low risk criteria, and that means women with lesions under two centimeters and with limited stromal invasion of the cervix based on the preoperative MRI or on the LEEP and cone, these women meeting low risk criteria, in fact, have a very low rate of parametrial extension, approximately less than 1%. And so the question is, in those women with low risk disease, perhaps there is no need to do radical surgery, and perhaps we can in fact do simple hysterectomy, which would be less radical, with less morbidity and better quality of life. So that is the concept of the SHAPE trial. We wanted to confirm this finding in a prospective, randomized study. We have entered 700 women on this study. 350 had a radical hysterectomy, 350 had a simple hysterectomy, and of course, lymph node evaluation was performed as well. And so the primary endpoint of the study was the three-year pelvic relapse rate at three years. And so the main important findings of the studies shown that they were equivalent in terms of age, stage, histology and grade. Importantly, 45% of the women were age 50 or younger, so young women. And what we found importantly is that the pelvic recurrence rate is very low in both groups, in the range of 3%, which is quite low. And the extra pelvic recurrences were also very low. The three-year pelvic recurrence, which was the main point or endpoint of the study, was 2.52% in the simple hyst and 2.17% in the radical hysterectomy, so 0.35% difference. And that meant that we reached the non-inferiority of the simple hysterectomy compared to the radical hysterectomy in the study. So that's the first important endpoint. The second element is we looked at surgical complications and we found that women who had a radical hysterectomy had three times more bladder injuries, and nearly twice the number of urethral complications. Additionally, urinary incontinence and urinary retention were statistically worse in the radical hysterectomy group, and it persisted over time, meaning that it stayed longer. The third important element of the study was the quality of life. We evaluated with the questionnaires, quality of life and sexual health, and all the domains that we analyze, which is sexual function, pain, distress, et cetera, were all in favor of the simple hysterectomy group. So in summary, for patients with low risk, early stage cervical cancer, the SHAPE trial showed non-inferiority at the three-year pelvic relapse rate. We also show a better surgical complication profile with a simple hysterectomy and better quality of life in sexual health in simple hysterectomy group. And so we believe based on the results of the SHAPE trial, that the new standard of care for the management of women with early stage, low risk disease, carefully evaluated and selected, we think the simple hysterectomy is the new standard of care, and it goes in line with surgical deescalation.

Related Videos

Colorectal Cancer

Cathy Eng, MD, and Thejus Jayakrishnan, MD, on Colorectal Cancer: Metabolomic Differences in Young-Onset vs Average-Onset Disease

Cathy Eng, MD, of Vanderbilt-Ingram Cancer Center, and Thejus Jayakrishnan, MD, of the Cleveland Clinic Taussig Cancer Institute, discuss significant differences in the citrate cycle, a core pathway of cellular metabolism associated with colorectal cancer. Metabolomic differences impacted by environmental exposures (arginine biosynthesis and dietary red meat) were also noted, suggesting possible links with younger age of onset in this disease (Abstract 3510).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, on Localized Prostate Cancer: Prognostic Impact of PSA Nadir

Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate cancer–specific, metastasis-free, and overall survival in patients receiving radiotherapy plus androgen-deprivation therapy for localized prostate cancer. These findings may help identify patients for therapy de-escalation trials (Abstract 5002).

Gynecologic Cancers

Bobbie J. Rimel, MD, and Mansoor R. Mirza, MD, on Endometrial Cancer: Patient-Reported Outcomes With Dostarlimab, Carboplatin, and Paclitaxel

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Mansoor R. Mirza, MD, of Denmark’s Rigshospitalet and Copenhagen University Hospital, discuss new findings on dostarlimab-gxly plus carboplatin/paclitaxel, which improved progression-free survival while maintaining health-related quality of life, further supporting its use as a standard of care in primary advanced or recurrent endometrial cancer (Abstract 5504).

Leukemia
COVID-19

Jennifer A. Woyach, MD, on New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax is not superior to ibrutinib plus obinutuzumab for treatment-naive older patients with chronic lymphocytic leukemia (CLL) in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to obinutuzumab plus venetoclax, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).

Lung Cancer

Nagla Abdel Karim, MD, on Small Cell Lung Cancer: SWOG S1929 Results on Atezolizumab Plus Talazoparib

Nagla Abdel Karim, MD, of the Inova Schar Cancer Institute, University of Virginia, discusses phase II data showing that maintenance atezolizumab plus talazoparib improved progression-free survival in Schlafen-11–selected patients with extensive-stage small cell lung cancer. This study demonstrated the feasibility of conducting biomarker-selected trials in this disease, paving the way for future evaluation of novel therapies in selected populations (Abstract 8504).

Advertisement

Advertisement




Advertisement